

## General

### Title

Sarcoma: proportion of patients with sarcoma who undergo palliative oncological treatment who die within 30 days of treatment.

### Source(s)

NHS Scotland, Scottish Cancer Taskforce. Sarcoma clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 May 20. 33 p. [30 references]

## Measure Domain

### Primary Measure Domain

Clinical Quality Measures: Outcome

### Secondary Measure Domain

Does not apply to this measure

## Brief Abstract

### Description

This measure is used to assess the proportion of patients with sarcoma who undergo palliative oncological treatment who die within 30 days of treatment.

This indicator will be reported by treatment modality, i.e., palliative radiotherapy, systemic anti-cancer therapy (SACT), etc., as opposed to a single figure.

This Cancer Quality Performance Indicator (QPI) is separated into two parts. Please refer to the related NQMC measure summary, [Sarcoma: proportion of patients with sarcoma who undergo surgical resection or oncological treatment with curative intent who die within 30 days of treatment](#).

Note from the National Quality Measures Clearinghouse: This measure is part of the QPIs collection. For more information, including a complete list of QPI measure sets, please visit the [Healthcare Improvement Scotland Web site](#).

## Rationale

Treatment related mortality is a marker of the quality and safety of the whole service provided by the multidisciplinary team (MDT) (NHS Quality

Improvement Scotland, 2008).

Outcomes of treatment, including treatment related morbidity and mortality should be regularly assessed.

Treatment should only be undertaken in individuals that may benefit from that treatment, that is, treatments should not be undertaken in futile situations. This Cancer Quality Performance Indicator (QPI) is intended to ensure treatment is given appropriately, and the outcome reported on and reviewed.

## Evidence for Rationale

NHS Quality Improvement Scotland. Management of bowel cancer services. Edinburgh (Scotland): NHS Quality Improvement Scotland; 2008 Mar. 41 p. [36 references]

NHS Scotland, Scottish Cancer Taskforce. Sarcoma clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 May 20. 33 p. [30 references]

## Primary Health Components

Sarcoma; palliative oncological treatment; death

## Denominator Description

All patients with sarcoma who undergo palliative oncological treatment

## Numerator Description

Number of patients with sarcoma who undergo palliative oncological treatment who die within 30 days of treatment (see the related "Numerator Inclusions/Exclusions" field)

## Evidence Supporting the Measure

### Type of Evidence Supporting the Criterion of Quality for the Measure

A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

A formal consensus procedure, involving experts in relevant clinical, methodological, public health and organizational sciences

### Additional Information Supporting Need for the Measure

Unspecified

### Extent of Measure Testing

The collection of data is piloted on a small number of patient records using a paper data collection form produced by Information Services Division (ISD). The aim is to identify any anomalies or difficulties with data collection prior to full implementation. At least one NHS board in each Regional Cancer Network participates in the pilot.

### Evidence for Extent of Measure Testing

## State of Use of the Measure

### State of Use

Current routine use

### Current Use

not defined yet

## Application of the Measure in its Current Use

### Measurement Setting

Ambulatory/Office-based Care

Ambulatory Procedure/Imaging Center

Hospices

Hospital Inpatient

Hospital Outpatient

### Professionals Involved in Delivery of Health Services

not defined yet

### Least Aggregated Level of Services Delivery Addressed

Single Health Care Delivery or Public Health Organizations

### Statement of Acceptable Minimum Sample Size

Unspecified

### Target Population Age

Unspecified

### Target Population Gender

Either male or female

# National Strategy for Quality Improvement in Health Care

## National Quality Strategy Aim

Better Care

## National Quality Strategy Priority

Making Care Safer

Prevention and Treatment of Leading Causes of Mortality

## Institute of Medicine (IOM) National Health Care Quality Report Categories

### IOM Care Need

End of Life Care

Living with Illness

### IOM Domain

Effectiveness

Safety

## Data Collection for the Measure

### Case Finding Period

Unspecified

### Denominator Sampling Frame

Patients associated with provider

### Denominator (Index) Event or Characteristic

Clinical Condition

Therapeutic Intervention

### Denominator Time Window

not defined yet

## Denominator Inclusions/Exclusions

### Inclusions

All patients with sarcoma who undergo palliative oncological treatment

### Exclusions

None

## Exclusions/Exceptions

not defined yet

## Numerator Inclusions/Exclusions

### Inclusions

Number of patients with sarcoma who undergo palliative oncological treatment who die within 30 days of treatment

Note: This indicator will be reported by treatment modality, i.e., palliative radiotherapy, systemic anti-cancer therapy (SACT), etc., as opposed to a single figure.

### Exclusions

None

## Numerator Search Strategy

Fixed time period or point in time

## Data Source

Electronic health/medical record

Paper medical record

## Type of Health State

Death

## Instruments Used and/or Associated with the Measure

Unspecified

## Computation of the Measure

### Measure Specifies Disaggregation

Measure is disaggregated into categories based on different definitions of the denominator and/or numerator

### Basis for Disaggregation

This indicator will be reported by treatment modality, i.e., palliative radiotherapy, systemic anti-cancer therapy (SACT), etc., as opposed to a single figure.

## Scoring

Rate/Proportion

## Interpretation of Score

Desired value is a lower score

## Allowance for Patient or Population Factors

not defined yet

## Standard of Comparison

not defined yet

## Prescriptive Standard

Target: less than 15%

## Evidence for Prescriptive Standard

NHS Scotland, Scottish Cancer Taskforce. Sarcoma clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 May 20. 33 p. [30 references]

## Identifying Information

### Original Title

QPI 11 (ii) – 30 day mortality.

### Measure Collection Name

Cancer Quality Performance Indicators (QPIs)

### Measure Set Name

Sarcoma

### Submitter

NHS Scotland - National Government Agency [Non-U.S.]

Scottish Cancer Taskforce - National Government Agency [Non-U.S.]

### Developer

NHS Scotland - National Government Agency [Non-U.S.]

Scottish Cancer Taskforce - National Government Agency [Non-U.S.]

## Funding Source(s)

Scottish Government

## Composition of the Group that Developed the Measure

Sarcoma QPI Development Group

## Financial Disclosures/Other Potential Conflicts of Interest

Unspecified

## Adaptation

This measure was not adapted from another source.

## Date of Most Current Version in NQMC

2016 May

## Measure Maintenance

The Cancer Quality Performance Indicators (QPIs) will be kept under regular review and be responsive to changes in clinical practice and emerging evidence. Formal reviews are conducted every 3 years and baseline checks each year.

## Date of Next Anticipated Revision

2017 Dec

## Measure Status

This is the current release of the measure.

## Measure Availability

Source document available from the [Healthcare Improvement Scotland Web site](#) .

For more information, contact the Healthcare Improvement Scotland at Gyle Square, 1 South Gyle Crescent, Edinburgh, Scotland EH12 9EB; Phone: 0131 623 4300; E-mail: [comments.his@nhs.net](mailto:comments.his@nhs.net); Web site: [www.healthcareimprovementscotland.org/](http://www.healthcareimprovementscotland.org/) .

## Companion Documents

The following is available:

- NHS Scotland. National cancer quality performance indicators: overview of development process. Edinburgh (Scotland): NHS Scotland;

## NQMC Status

This NQMC summary was completed by ECRI Institute on May 16, 2017.

## Copyright Statement

No copyright restrictions apply.

## Production

## Source(s)

NHS Scotland, Scottish Cancer Taskforce. Sarcoma clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 May 20. 33 p. [30 references]

## Disclaimer

### NQMC Disclaimer

The National Quality Measures Clearinghouse<sup>â„¢</sup> (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the [NQMC Inclusion Criteria](#).

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.